BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Plureon Corporation Announces Diabetes Research And Development Agreement With Becton, Dickinson And Company (BDX)


10/19/2005 5:13:22 PM

WINSTON-SALEM, N.C., Oct. 14 /PRNewswire/ -- Plureon Corporation ("Plureon") today announced that it has entered into an agreement with BD (Becton, Dickinson and Company) in the field of diabetes research and development using Plureon's platform stem cell technology. Plureon's stem cells may be obtained from placental tissues that are usually discarded as medical waste after birth.

Under the agreement, BD will sponsor Plureon's research efforts for up to three years and will be responsible for further development of the technology. Plureon retains rights to provide future manufacturing and medical education support to BD.

Mr. Hal Eason, Chairman, President and CEO of Plureon, said, "We are extremely pleased to have BD as our partner in the field of diabetes. BD is a world leader in diabetes care, with an excellent understanding of patients, researchers and practitioners. BD also has unique technology assets to accelerate the research and development of Plureon's technology."

About Plureon

Plureon is a privately held biotechnology company based in Winston-Salem, North Carolina. Plureon has licensed from Children's Hospital Boston (a Harvard Medical School teaching affiliate) the exclusive worldwide rights to its patents pertaining to a novel type of stem cell discovered at the hospital's Laboratory for Cell Therapy and Tissue Engineering. Plureon's stem cells are not sourced from human embryonic tissues, yet may be differentiated into many other cell types, including bone, cardiac muscle, nerves, liver and pancreatic cells.

Contact: Hal Eason Plureon Corporation (336) 499 2673 news@plureon.com

Plureon Corporation

CONTACT: Hal Eason, Plureon Corporation, +1-336-499-2673, ornews@plureon.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES